NCT02559687View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)

PHASE2CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

December 2, 2015

Primary Completion Date

July 30, 2018

Study Completion Date

October 29, 2021

Conditions

Esophageal CarcinomaEsophagogastric Junction Carcinoma

Interventions

BIOLOGICAL

pembrolizumab

IV Q3W

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02559687 - Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | Biotech Hunter | Biotech Hunter